熊去氧胆酸(优思弗)治疗丙型肝炎肝硬化的临床效果观察

Observation of clinical effects of ursodeoxycholic acid(Ursofalk) in the treatment of post hepatitis C cirrhosis

目的探讨熊去氧胆酸（优思弗）治疗丙型肝炎肝硬化的疗效。方法 89例研究对象均为2013年10月-2015年10月期间来我院进行治疗的丙型肝炎肝硬化患者,按照治疗方法分组,对照组44例,单独应用水飞蓟宾葡甲胺治疗,研究组45例,应用水飞蓟宾葡甲胺联合熊去氧胆酸（优思弗）治疗,3个月为一个治疗疗程,2个疗程后对比两组的临床疗效。结果 治疗后两组ALT、AST、TBIL、HCV RNA均较治疗前明显降低,研究组降低的程度高于对照组,差异有统计学意义（P〈0.05）。治疗后两组PC-Ⅲ、HA、LN、Ⅳ-C均较治疗前明显降低,且研究组降低的程度明显高于对照组,差异有统计学意义（P〈0.05）。结论 熊去氧胆酸治疗丙型肝炎肝硬化疗效确切,可有效改善患者的临床症状及血清纤维化指标,可作为一种治疗丙型肝炎肝硬化的有效方法在临床推广应用。

Objective To explore the curative effects of ursodeoxycholic acid （Ursofalk） in the treatment of post hepatitis C cirrhosis. Methods A total of 89 patients with post hepatitis C cirrhosis who were treated in our hospital from October 2013 to October 2015 were selected as research subjects. They were assigned to groups according to different therapeutic methods. 44 patients in the control group were given silybin meglumine alone for the treatment, and 45 patients in the research group were given silybin meglumine combined with ursodeoxycholie acid（Ursofalk） for the treatment. 3 months were one course of treatment. Clinical curative effects were compared between the two groups after two courses of treatment. Results ALT, AST, TBIL, HCV RNA in the two groups after the treatment were all significantly reduced compared with those before the treatment, and the reduction degree in the research group was higher than that in the control group. The differences between the two groups were statistically significant （P〈0.05）. PC-Ⅲ, HA, LN and Ⅳ-C in the two groups after the treatment were significantly reduced compared with those before the treatment, and the re- duction degree in the research group was higher than that in the control group. The differences between the two groups were statistically significant（P〈0.05）. Conclusion The curative effects of ursodeoxyeholic acid in the treatment of post hepatitis C cirrhosis are exact, which is able to effectively improve patients＇ clinical symptoms and hepatic fibrosis indices. This method can be clinical promoted and applied as an effective method of treating post hepatitis C cirrhosis.